ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 12,632 shares, an increase of 143.4% from the June 15th total of 5,190 shares. Based on an average trading volume of 18,635 shares, the short-interest ratio is currently 0.7 days. Approximately 1.5% of the company’s stock are sold short.
ProShares Ultra Nasdaq Biotechnology Trading Down 3.0%
Shares of NASDAQ BIB opened at $99.86 on Tuesday. The firm has a market cap of $83.88 million, a PE ratio of 20.68 and a beta of 1.19. ProShares Ultra Nasdaq Biotechnology has a 1-year low of $48.50 and a 1-year high of $110.25. The company has a fifty day moving average price of $88.19 and a 200 day moving average price of $84.84.
Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIB. Franklin Resources Inc. acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth about $32,000. Citadel Advisors LLC acquired a new position in ProShares Ultra Nasdaq Biotechnology during the third quarter valued at approximately $307,000. Finally, Kaizen Financial Strategies acquired a new position in ProShares Ultra Nasdaq Biotechnology during the fourth quarter valued at approximately $424,000.
About ProShares Ultra Nasdaq Biotechnology
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
See Also
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- CEOs Sell Millions Worth of These 3 Big Name Stocks—What It Means for Investors
- Fission for Profits: Unlocking America’s Uranium Vault
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
